Full Press Release Details
NEW YORK, April 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
May 2-4: Aegis Virtual Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at this virtual conference on Thursday, May 4, 2023, at 11:00 am ET. A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
May 3-5: 7th ISIRV-AVG Conference, Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present preclinical data on the antiviral properties of dihydroorotate dehydrogenase (DHODH) inhibitors in an oral presentation at this conference in Seattle, WA. The presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections
Abstract Number: AASU0039
Session: Preclinical Development
Date: Wednesday, May 3, 2023
Time: 3:00 - 3:15 pm PT (6:00 - 6:15 pm ET)
May 4-7: 8th European Congress of Virology 2023. Dr. Alexandra Herrmann, Program Manager Virology at Immunic, will present preclinical broad-spectrum antiviral activity data for newly developed DHODH inhibitors in a poster presentation at this conference in Gdańsk, Poland. The poster will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections
Session: Poster session 1, Antivirals
Date: Friday, May 5, 2023
Time: 7:00 pm CET (1:00 pm ET)
May 6-9: Digestive Disease Week 2023. Franziska Buriánek, M.D., Senior Medical Director at Immunic, will present phase 1 clinical data of IMU-856 in healthy human subjects in a virtual e-poster at this conference in Chicago, IL. The poster will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: First In Human Trial of IMU-856, an Orally Available Regulator Of Barrier Function For The Treatment Of Celiac Disease
ePoster Number: EP63
Session: AGA Celiac Disease and Gluten Related Disorders
Date: Saturday, May 6, 2023
Time: 9:30 am - 4:00 pm CT (10:30 am - 5:00 pm ET)
May 14-16 and 22-23: 23rd Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview on Monday, May 15, 2023, at 11:44 am IST (6:44 am ET) as part of the "Autoimmune, Inflammation and Thrombosis" track at this conference in Dublin, Ireland.
May 18-21: XXII National Congress of Neurology. Sonya Ivanova Hristova-Chakmakova, M.D., Assistant Professor, Multiprofile Hospital for Active Treatment in Neurology and Psychiatry «St. Naum», Sofia, Bulgaria, will present a poster presentation on the results of Immunic's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis at this conference in Golden Sands, Bulgaria. The poster will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: EMPhASIS: An overview of trial design, efficacy and safety of vidofludimus calcium in the phase 2 trial in relapsing-remitting multiple sclerosis
Session: Second Poster Session: Inflammatory, Demyelinating and autoimmune CNS diseases
Date: Sunday, May 21, 2023
Time: 9:30 am - 12:30 pm EET (2:30 - 5:30 am ET)
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis and which has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently being evaluated in a clinical proof-of-concept trial. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict on clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Head of Investor Relations and Communications
Rx Communications Group
SOURCE Immunic, Inc.
21 %
more press release views with